

SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) PRIVACY	1a. COUNTRY COSTA RICA	2. DATE OF BIRTH			2a. AGE 64 Years	3. SEX Female	3a. WEIGHT Unk	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION <input type="checkbox"/> PATIENT DIED <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY <input type="checkbox"/> LIFE THREATENING
		Day	Month	Year				Day	Month	Year	
			PRIVACY					Unk			

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)
Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)
Did not did her well [Ill-defined disorder]
Made her half dizzy [Dizziness]

Case Description: Patient Demographics: 64 Years old Female

Event(s): Did not did her well, Made her half dizzy

Suspect Product(s) (Name, IFU): cymbalta 30mg (duloxetine hydrochloride) for treatment of For fibromyalgia pain

(Continued on Additional Information Page)

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1) Cymbalta 30mg (Duloxetine Hydrochloride) Capsule, 30 mg		20. DID REACTION ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA
15. DAILY DOSE(S) #1) 1 dosage form, daily	16. ROUTE(S) OF ADMINISTRATION #1) Oral	
17. INDICATION(S) FOR USE #1) For fibromyalgia pain (Fibromyalgia)		21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA
18. THERAPY DATES(from/to) #1) 2021 / 2023	19. THERAPY DURATION #1) Unknown	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) #1) ALTRULINE (SERTRALINE HYDROCHLORIDE) Unknown ; Unknown #2) IRBESARTAN (IRBESARTAN) Unknown ; Unknown								
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) <table border="0"> <tr> <td>From/To Dates</td> <td>Type of History / Notes</td> <td>Description</td> </tr> <tr> <td>Unknown</td> <td>Medical Condition very old</td> <td>Movement disorder (Movement disorder)</td> </tr> </table>			From/To Dates	Type of History / Notes	Description	Unknown	Medical Condition very old	Movement disorder (Movement disorder)
From/To Dates	Type of History / Notes	Description						
Unknown	Medical Condition very old	Movement disorder (Movement disorder)						

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER Eli Lilly Interamerica Inc (AR Branch) Tronador 4890 - Piso 12 Buenos Aires, Capital Federal CP: 1430 ARGENTINA Phone: 54 1145464000		26. REMARKS
	24b. MFR CONTROL NO. CR202507002763	
24c. DATE RECEIVED BY MANUFACTURER 28-JUN-2025	24d. REPORT SOURCE <input type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input checked="" type="checkbox"/> OTHER: Spontaneous	
DATE OF THIS REPORT 03-JUL-2025	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

25b. NAME AND ADDRESS OF REPORTER
 NAME AND ADDRESS WITHHELD.

 NAME AND ADDRESS WITHHELD.

 NAME AND ADDRESS WITHHELD.

03-Jul-2025 05:08

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

Action(s) Taken: cymbalta 30mg (duloxetine hydrochloride) - Drug Discontinued

Event Outcome(s): Did not did her well (Unknown), Made her half dizzy (Unknown)

Reporter's Opinion of Relatedness: cymbalta 30mg (duloxetine hydrochloride) - Did not did her well (Not Reported) , Made her half dizzy (Not Reported)